HOME >> BIOLOGY >> NEWS
Halfway human

Delson recreated the shape of SM3's skull using coordinates from some 200 points on its surface. He did the same for 23 other specimens-11 H. erectus, 10 modern H. sapiens, and 2 archaic H. sapiens. With this information, his computer program arranged the specimens according to their similarity, placing SM3 just about squarely between the erectus and modern humans-while even the archaic H. sapiens fell in among the erectus specimens.

Next, Delson told the computer that there were categories called "erectus", "sapiens" and "archaic", and asked it to find features that would force known members of each group closer together. Again the program lumped archaic H. sapiens in with the erectus specimens. And when Delson asked the computer to categorise the unknown SM3 it still ended up floating between the two main groups, though a bit closer to the erectus cluster. Delson therefore feels comfortable designating SM3 as an erectus, albeit a strange one. He suggests three possible explanations for her odd looks. She could have been an aberrant individual. She could be a member of a hitherto unknown population of Indonesian H. erectus with bulging foreheads. Or, he acknowledges, she could represent "a population evolving in the direction of modern humans". The last explanation is music to the ears of multiregionalists. "That is very daring for him to say," says Wolpoff. "If you thought Homo sapiens began in Africa, as I know [Delson] does, then something in Indonesia has no business evolving in that direction."

But SM3 doesn't even have to be the long-awaited missing link to be troublesome. The finding that she fits so poorly into existing species categories seems to highlight an ongoing problem in paleoanthropology. The experts still argue over what constitutes H. erectus, an enormous group that has been called "the muddle in the middle" because it spans more than a million years and includes many specimens, from Indonesia, Asia and Africa, that don't neces
'"/>

Contact: Claire Bowles
claire.bowles@rbi.co.uk
44-207-331-2751
New Scientist
10-Apr-2001


Page: 1 2 3 4 5 6 7 8

Related biology news :

1. Climate change plus human pressure caused large mammal extinctions in late Pleistocene
2. Lycopene slows human prostate tumour growth in mice and combined with vitamin E is even better
3. Most recent common ancestor of all living humans surprisingly recent
4. Wildlife Conservation Society hosts public symposium on human-wildlife diseases
5. Bronfenbrenner book sums up human development
6. No role for simian virus 40 in human pleural mesotheliomas
7. Sugar-coated sea urchin eggs could have sweet implications for human fertility
8. Serotonin metabolites in mollusks suggest pathways for human therapies
9. Wrapping a memory with an experience, capacity for recollection detected in non-human species
10. Viral suspect for amphibian decline traced to human spread through bait
11. Recent evolution at a single gene may have brought down heart disease risk in some human groups

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Halfway human

(Date:12/10/2014)... 08, 2014 Research and Markets ... the "Biometrics Market in Japan 2014-2018" ... http://photos.prnewswire.com/prnh/20130307/600769 The integration of ... rural banking and upgradation of the driver,s license ... the market. Besides the aforementioned projects, biometrics is ...
(Date:12/5/2014)... 2014 Increased emphasis on product quality, ... testing and inspection technologies. The convergence of industries ... range of innovative test solutions. This trend is ... which is generally more inclined towards communication, media ... strategies of test equipment vendors will cater to ...
(Date:12/4/2014)... 3, 2014  Crossmatch™, a leading provider of ... DigitalPersona ® Pro Enterprise software and U.are.U ... throughout First Bank branch locations in ... and Virginia. First Bank, a progressive community ... North Carolina , selected the Crossmatch biometrics-based ...
Breaking Biology News(10 mins):Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3
(Date:12/19/2014)... YORK , Dec. 18, 2014 Relmada ... therapies for the treatment of chronic pain, announced the ... today. "This was a transformational year in ... promising future for our company," said Sergio Traversa ... year, we have executed on key financial, human resource ...
(Date:12/17/2014)... N.J. (PRWEB) December 17, 2014 ... (Euronext: IPN; ADR: IPSEY), today announced ... (referred to as Somatuline®) was approved by the ... treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in adult ... advanced or metastatic disease to improve progression-free survival ...
(Date:12/17/2014)... 17, 2014 Audacity, a leading California-based ... member of the Huntsworth Health Group, is proud to ... team. In her role, Gonzales will serve as Senior ... incredibly honored to welcome a talent of Jamie’s caliber ... Gaëtan Fraikin. “She is a proven healthcare innovation leader ...
(Date:12/17/2014)... Mass. , Dec. 17, 2014   Synageva ... biopharmaceutical company developing therapeutic products for rare disorders, announced ... Conference being held in San Francisco, CA. ... President and Chief Executive Officer, will present on Monday, ... EST).  The presentation will be webcast live and may ...
Breaking Biology Technology:Relmada Therapeutics Announces Results of Annual Shareholders Meeting 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 5Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 6Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 7Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 8Audacity Welcomes Healthcare Communications Expert Jamie Gonzales as Senior Vice President of Client Services 2
Cached News: